Vaxcyte Prices $1B Raise at $64, 40% Conversion Premium

Vaxcyte, Inc. (Nasdaq: PCVX) announced on Oct. 6, 2026 the pricing of concurrent public offerings expected to raise roughly $1 billion in gross proceeds, split evenly between $500 million of common stock and pre-funded warrants and $500 million of 1.50% convertible senior notes due 2032. Shares priced at $64.00, pre-funded warrants at $63.999 with a $0.001 exercise price, and the notes carry an initial conversion price of about $89.60, a 40.0% premium to the stock offering price.

Context — Why a $1 Billion Raise Now?

Vaxcyte is a clinical-stage vaccine developer with no approved product. The company said it intends to use net proceeds to fund clinical development of its VAX-31 adult and pediatric programs, manufacturing scale-up, and commercial preparations for an anticipated U.S. adult launch.

The report gives no prior financing for comparison, so the scale of this raise has to be read against what the company said it will spend it on. That list is unusually specific for a clinical-stage issuer: named trials, named data readouts, and named manufacturing investments rather than a generic research budget.

On the adult side, Vaxcyte cited the ongoing VAX-31 Phase 3 program, including the OPUS-2 trial evaluating concomitant administration with a seasonal influenza vaccine and the OPUS-3 trial in adults who previously received a pneumococcal vaccine. The company said both are enrolled, and it flagged a planned manufacturing consistency study plus anticipated topline safety, tolerability and immunogenicity data announcements from those studies.

On the pediatric side, Vaxcyte pointed to the VAX-31 infant Phase 2 dose-finding study, which it said is enrolled, and anticipated topline data from the primary three-dose immunization series and booster dose.

The timing reflects a company funding a pipeline before it has revenue. The report does not disclose Vaxcyte's cash balance, burn rate or how long the proceeds are expected to last, so the raise cannot be measured against a stated runway.

Data — What the Numbers Show

The offering combines three instruments priced together. Common stock: 7,412,500 shares at $64.00. Pre-funded warrants: 400,000 units at $63.999, exercisable at $0.001 per share. Convertible notes: $500 million principal at 1.50% per annum.

Instrument	Size	Price / Rate	Key Term
Common stock	7,412,500 shares	$64.00	30-day option on 1,171,875 more shares
Pre-funded warrants	400,000 warrants	$63.999	$0.001 exercise price
Convertible notes	$500M principal	1.50% coupon	$89.60 conversion price

The stock and warrant offering grosses approximately $500 million; the note offering grosses $500 million, both before underwriting discounts, commissions and other expenses, and both excluding any pre-funded warrant exercises and assuming no over-allotment exercise.

On the notes, the conversion rate is 11.1607 shares per $1,000 principal, equal to roughly $89.60 per share — about 40.0% above the $64.00 equity price. Interest is payable semi-annually in arrears on April 15 and October 15, starting April 15, 2027. The notes mature Oct. 15, 2032 unless repurchased, redeemed or converted earlier.

Before July 15, 2032, holders may convert only on certain events; from that date they may convert any time until the second scheduled trading day before maturity. Vaxcyte will settle conversions in cash, stock or a combination, at its election. The report gives no current market price for PCVX, so the premium is measured against the deal price rather than the market.

Analysis — What the Structure Signals

The structure splits the raise between instruments that dilute immediately and one that dilutes only on a much higher share price. The pre-funded warrants are economically near-identical to stock, since their $0.001 exercise price makes the $63.999 purchase price effectively the whole cost. The convertibles sit 40% out of the money at pricing.

The two offerings are independent. Vaxcyte said completion of the stock and warrant offering is not contingent on the note offering, and vice versa — a detail that matters if one book fails to clear. The company also granted underwriters a 30-day option on 1,171,875 additional shares and a separate 30-day option on $75 million more principal of notes, solely to cover over-allotments.

Redemption terms favor the issuer. Vaxcyte may call the notes for cash on or after Oct. 22, 2029, but only if the stock trades above 130% of the conversion price for a specified period. It may also redeem the notes in whole if outstanding principal falls below 10% of the amount issued. On a fundamental change, holders may require repurchase at principal plus accrued interest, subject to a limited exception.

The counter-argument is dilution. Existing holders absorb 7,412,500 new shares plus 400,000 warrant shares, and more if the over-allotment is exercised — against a commercial launch that has not happened. The report gives no share count outstanding, so the percentage dilution cannot be calculated from the disclosed figures.

Positioning follows the structure: convertible funds buy the notes for the coupon and the equity optionality, while the equity book absorbs the near-term supply. The underwriter syndicate is broad, with Jefferies, Leerink Partners, BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC and Guggenheim Securities as joint book-running managers on the stock offering, Mizuho as bookrunner and BTIG as lead manager.

Outlook — What to Watch Next

The offerings are expected to close Oct. 9, 2026, subject to customary closing conditions. That date is the first checkpoint: if conditions are not met, the proceeds do not arrive.

After closing, the catalysts the company itself named are the topline data announcements from the VAX-31 adult Phase 3 studies — OPUS-2, OPUS-3 and the planned manufacturing consistency study — and from the infant Phase 2 dose-finding study, covering the primary three-dose series and booster dose. The report gives no dates for those readouts.

The commercial milestones to track are the manufacturing capacity build-out and inventory build ahead of a potential U.S. adult launch of VAX-31, which the company said the proceeds will fund. The report names no price levels or technical thresholds for PCVX, so no support or resistance can be cited.

Frequently Asked Questions

What does the Vaxcyte offering mean for existing PCVX shareholders?

Existing holders face dilution from 7,412,500 new shares and 400,000 pre-funded warrant shares, plus up to 1,171,875 more if underwriters exercise the stock over-allotment. The notes dilute only if converted, which requires the stock to reach about $89.60. The company did not disclose its shares outstanding, so the exact percentage cannot be computed from the report.

Why did Vaxcyte include convertible notes instead of only selling stock?

The notes carry a 1.50% coupon and a conversion price roughly 40% above the equity offering price, so they raise $500 million with no immediate share issuance. Vaxcyte can settle conversions in cash, stock or a mix, at its election. Interest begins accruing toward the first payment on April 15, 2027.

What happens if the offerings do not close?

Each offering stands alone. Vaxcyte said completion of the stock and pre-funded warrant offering is not contingent on the note offering, and the note offering is not contingent on the stock offering, so one could close without the other. Both are expected to close Oct. 9, 2026, subject to customary closing conditions.

Bottom Line

Vaxcyte is raising about $1 billion at $64.00 a share to fund VAX-31 trials and a commercial build-out it has not yet earned revenue from.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.